Clinical Trial Update: A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A phase III trial evaluating reduced frequency pembrolizumab therapy as first-line treatment for advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Imperial College London | Conditions: Lung Cancer, Nonsmall Cell | Phase 3 | Status: RECRUITING